NCT05698771 (NAD-brain) is a Phase 1 clinical trial of Nicotinamide Riboside (NR) in Healthy, sponsored by Haukeland University Hospital.

Who is sponsoring NCT05698771?

NCT05698771 is sponsored by Haukeland University Hospital.

What drugs are being tested in NCT05698771?

Interventions in NCT05698771: Nicotinamide Riboside (NR), nicotinamide mononucleotide, Nicotinamide Riboside (NR), Nicotinamide Riboside (NR).

Is NCT05698771 still recruiting?

NCT05698771 is currently completed. Last updated 17 January 2025.

Last reviewed 2025-01-17 · How we verify

NCT05698771: NAD-brain

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy

Completed Phase 1 Last updated 17 January 2025

What this trial tests

Phase 1 trial testing Nicotinamide Riboside (NR) in Healthy in 12 participants. Completed in 4 March 2024.

Timeline

17 September 2022

Primary endpoint
4 March 2024

4 March 2024

Quick facts

Lead sponsor	Haukeland University Hospital
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	17 September 2022
Primary completion	4 March 2024
Estimated completion	4 March 2024
Sites	1 location across Norway

Drugs / interventions tested

Nicotinamide Riboside (NR) — full drug profile →
nicotinamide mononucleotide — full drug profile →
Nicotinamide Riboside (NR) — full drug profile →
Nicotinamide Riboside (NR) — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Haukeland University Hospital

Who can join

Adults 35 to 85, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the NAD-brain study is to determine the blood and brain pharmacokinetics of NAD replenishment therapy (NRT) using Nicotinamide Riboside (NR) or Nicotinamide Mononucleotide (NMN).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer's disease.
Ketron GL, Grun F, Grill JD, Feldman HH, et al · · 2025 · cited 3× · PMID 40069789 · DOI 10.1186/s13195-025-01693-y
The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation.
Berven H, Svensen M, Eikeland H, Tvedten N, et al · · 2026 · PMID 41858901 · DOI 10.1016/j.isci.2026.114764

Verify or expand the search:

Other trials of Nicotinamide Riboside (NR)

Trials testing the same drug.

NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants · Phase 2, PHASE3 · not yet recruiting
NCT07284225 — Acute Effects of Nicotinamide Riboside on Polysomnography-Measured Sleep Structure in Healthy Adults · NA · not yet recruiting
NCT06971224 — NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals · Phase 2 · recruiting
NCT05517122 — Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults · NA · completed
NCT04112043 — Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial) · Phase 1 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Haukeland University Hospital trials

Trials by the same sponsor.

NCT07450105 — Intensive Dialectical Behavior Therapy for Self-Harm and Suicidal Behavior in Youth: A Pilot Study · NA · not yet recruiting
NCT07450092 — Prehospital Use of Forced Air Warming · NA · enrolling by invitation
NCT07268716 — Assess the Efficacy of Tailored Patient Information and Voluntary Patient-managed Outpatient Digital Follow-up (I-POD) a · NA · not yet recruiting
NCT07392697 — The Intravenous Amino Acid Therapy for Vascular Rigidity in End Stage Renal Disease · NA · not yet recruiting
NCT07304219 — Physical Activity Based Treatment for Youth With Depression and Anxiety · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05698771 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Haukeland University Hospital
Last refreshed: 17 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05698771.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing